Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5α-Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement

Open access

Abstract

CONTEXT: Mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane] is the first-line treatment for metastatic adrenocortical carcinoma (ACC) and is also regularly used in the adjuvant setting after presumed complete removal of the primary tumor. Mitotane is considered an adrenolytic substance, but there is limited information on distinct effects on steroidogenesis. However, adrenal insufficiency and male hypogonadism are widely recognized side effects of mitotane treatment. OBJECTIVE: Our objective was to define the impact of mitotane treatment on in vivo steroidogenesis in patients with ACC. SETTING AND DESIGN: At seven European specialist referral centers for adrenal tumors, we analyzed 24-h urine samples (n = 127) collected from patients with ACC before and during mitotane therapy in the adjuvant setting (n = 23) or for metastatic ACC (n = 104). Urinary steroid metabolite excretion was profiled by gas chromatography/mass spectrometry in comparison with healthy controls (n = 88). RESULTS: We found a sharp increase in the excretion of 6β-hydroxycortisol over cortisol (P < 0.001), indicative of a strong induction of the major drug-metabolizing enzyme cytochrome P450 3A4. The contribution of 6β-hydroxycortisol to total glucocorticoid metabolites increased from 2% (median, interquartile range 1-4%) to 56% (39-71%) during mitotane treatment. Furthermore, we documented strong inhibition of systemic 5α-reductase activity, indicated by a significant decrease in 5α-reduced steroids, including 5α-tetrahydrocortisol, 5α-tetrahydrocorticosterone, and androsterone (all P < 0.001). The degree of inhibition was similar to that in patients with inactivating 5α-reductase type 2 mutations (n = 23) and patients receiving finasteride (n = 5), but cluster analysis of steroid data revealed a pattern of inhibition distinct from these two groups. Longitudinal data showed rapid onset and long-lasting duration of the observed effects. CONCLUSIONS: Cytochrome P450 3A4 induction by mitotane results in rapid inactivation of more than 50% of administered hydrocortisone, explaining the need for doubling hydrocortisone replacement in mitotane-treated patients. Strong inhibition of 5α-reductase activity is in line with the clinical observation of relative inefficiency of testosterone replacement in mitotane-treated men, calling for replacement by 5α-reduced androgens.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2012-2851

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Research works printed but not linked: 1

  1. Allolio, 1985, Comparison between hydrocortisone and cortisone acetate as replacement therapy in adrenocortical insufficiency., Aktuelle Endokrinologie Stoffwechsel, 6, 35

Cited by

See all 154

Metadata

Authors
Chortis, V., Taylor, A. E., Schneider, P., Tomlinson, J. W., Hughes, B. A., O'Neil, D. M., Libé, R., Allolio, B., Bertagna, X., Bertherat, J., Beuschlein, F., Fassnacht, M., Karavitaki, N., Mannelli, M., Mantero, F., Opocher, G., Porfiri, E., Quinkler, M., Sherlock, M., Terzolo, M., Nightingale, P., Shackleton, C. H. L., Stewart, P. M., Hahner, S., & Arlt, W.
Affiliations
  • University of Birmingham (GB)
  • Centre for Endocrinology, Diabetes, and Metabolism (V.C., A.E.T., P.S., J.W.T., B.A.H., D.M.O'N., M.S., C.H.L.S., P.M.S., W.A.), Birmingham B15 2TT, United Kingdom
  • Inserm (FR)
  • University of Würzburg (DE)
  • Department of Endocrinology (R.L., J.B., X.B.), Institut National du Cancer Cortico-Medullo Tumeurs Endocrines, Cochin Hospital, Institut Cochin, Institut National de la Santé et de la Recherche Médicale Unité 1016, René Descartes University, Paris, F-75006 France
  • LMU Klinikum (DE)
  • John Radcliffe Hospital (GB)
  • University of Florence (IT)
  • University of Padua (IT)
  • Familial Cancer Clinic (G.O.), I-35100 Padova, Italy
  • Charité – Universitätsmedizin Berlin (DE)
  • Trinity College Dublin (IE)
  • University of Turin (IT)
  • National Health Service (GB)
Corresponding author
Arlt, Wiebke
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2013-01-01
Volume
98
Issue
1
Pages
161-171
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W1967949880
Cited by
154
References
48
Citations by year
2026: 4 · 2025: 13 · 2024: 8 · 2023: 4 · 2022: 14 · 2021: 10 · 2020: 17 · 2019: 8 · 2018: 17 · 2017: 5 · 2016: 11 · 2015: 14 · 2014: 19 · 2013: 10
FWCI
14.00
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by-nc)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
  • Florence Research (University of Florence) (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion, cc-by-nc)
  • Padua Research Archive (University of Padova) (submittedVersion)
Funders
  • National Institute for Health and Care Research (FP7/2007–2013, ACF-2010-09-004, NF-SI-0508-10356)
  • European Commission (2007–2013, FP7 2007-2013, 259735, FP7/2007)
  • Medical Research Council (FP7/20072013, G0801473)
Topics
  • Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
Keywords
mitotane, adrenocortical carcinoma, CYP3A4 induction, 5α-reductase inhibition, steroidogenesis, 6β-hydroxycortisol, urinary steroid metabolites, adrenal insufficiency, male hypogonadism, glucocorticoid replacement therapy, androgen replacement, adjuvant therapy, finasteride
MeSH terms
Adolescent, Adrenal Cortex Neoplasms, Adult, Aged, Aged, 80 and over, Androgens, Enzyme Activation, Female, Glucocorticoids, Health Services Needs and Demand, Humans, Male, Middle Aged, Mitotane, 3-Oxo-5-alpha-Steroid 4-Dehydrogenase, Down-Regulation, Up-Regulation, Adrenocortical Carcinoma, Antineoplastic Agents, Hormonal, Hormone Replacement Therapy, Cytochrome P-450 CYP3A, Young Adult, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.